Edrecolomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | EpCAM (17-1A) |
| Clinical data | |
| Trade names | Panorex |
| Identifiers | |
| CAS Number |
156586-89-9  |
| ATC code | L01XC01 |
| ChemSpider | none |
 (what is this?) (verify) | |
Edrecolomab (MAb17-1A, trade name Panorex) is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.
Preliminary studies had shown promise of a possible use in patients with stage III colorectal carcinoma (with metastasis to the lymph nodes).[1][2] However, when put to a phase III study (2,761 patients) it did not provide any benefit when compared to conventional chemotherapeutic agents.[3] No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.[4]
Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer.
References
- ↑ Riethmüller G, Schneider-Gädicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet. 1994;343(8907):1177-83. PMID 7909866
- ↑ Fields AL, Keller AM, Schwartzberg L et al. Edrecolomab (17-1A antibody) in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study (abstract). Proc Am Soc Clin Oncol. 2002;21:128a.
- ↑ Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002;360(9334):671-7. doi:10.1016/S0140-6736(02)09836-7 PMID 12241873
- ↑ Colacchio TA, Niedzwicki D, Compton C, et al. Phase III trial of adjuvant immunotherapy with MoAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). Proc Am Soc Clin Oncol. 2004;23:251a.
| ||||||||||||||||||||||||||||||